AU2009266953A1 - Isoindolone derivatives as MEK kinase inhibitors and methods of use - Google Patents

Isoindolone derivatives as MEK kinase inhibitors and methods of use Download PDF

Info

Publication number
AU2009266953A1
AU2009266953A1 AU2009266953A AU2009266953A AU2009266953A1 AU 2009266953 A1 AU2009266953 A1 AU 2009266953A1 AU 2009266953 A AU2009266953 A AU 2009266953A AU 2009266953 A AU2009266953 A AU 2009266953A AU 2009266953 A1 AU2009266953 A1 AU 2009266953A1
Authority
AU
Australia
Prior art keywords
alkyl
cr19r20
nhc
carbocyclyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009266953A
Other languages
English (en)
Other versions
AU2009266953A2 (en
Inventor
Emanuela Gancia
Robert Andrew HEALD
Philip Jackson
Stephen Price
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41128054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009266953(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2009266953A1 publication Critical patent/AU2009266953A1/en
Publication of AU2009266953A2 publication Critical patent/AU2009266953A2/en
Priority to AU2014250642A priority Critical patent/AU2014250642A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AU2009266953A 2008-07-01 2009-07-01 Isoindolone derivatives as MEK kinase inhibitors and methods of use Abandoned AU2009266953A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014250642A AU2014250642A1 (en) 2008-07-01 2014-10-15 Isoindolone derivatives as MEK kinase inhibitors and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7743208P 2008-07-01 2008-07-01
US61/077,432 2008-07-01
PCT/US2009/049449 WO2010003022A1 (en) 2008-07-01 2009-07-01 Isoindolone derivatives as mek kinase inhibitors and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014250642A Division AU2014250642A1 (en) 2008-07-01 2014-10-15 Isoindolone derivatives as MEK kinase inhibitors and methods of use

Publications (2)

Publication Number Publication Date
AU2009266953A1 true AU2009266953A1 (en) 2010-01-07
AU2009266953A2 AU2009266953A2 (en) 2011-01-27

Family

ID=41128054

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009266953A Abandoned AU2009266953A1 (en) 2008-07-01 2009-07-01 Isoindolone derivatives as MEK kinase inhibitors and methods of use

Country Status (16)

Country Link
US (1) US8492427B2 (https=)
EP (1) EP2307364B1 (https=)
JP (1) JP5615274B2 (https=)
KR (1) KR20110028376A (https=)
CN (1) CN102137843A (https=)
AU (1) AU2009266953A1 (https=)
BR (1) BRPI0910200A2 (https=)
CA (1) CA2727252A1 (https=)
CL (1) CL2010001637A1 (https=)
ES (1) ES2426096T3 (https=)
IL (1) IL209892A0 (https=)
MX (1) MX2010014565A (https=)
PE (1) PE20110424A1 (https=)
RU (1) RU2495028C2 (https=)
WO (1) WO2010003022A1 (https=)
ZA (1) ZA201008962B (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
US20150265679A1 (en) 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
WO2015002729A2 (en) 2013-06-13 2015-01-08 Biomatrica, Inc. Cell stabilization
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
JP6403172B2 (ja) * 2013-10-25 2018-10-10 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用
AU2015210833B2 (en) 2014-02-03 2019-01-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
CN103922992B (zh) * 2014-04-25 2015-09-02 温州大学 一种抗癌活性吲哚酮衍生物、合成方法及其用途
ES2786373T3 (es) 2014-06-10 2020-10-09 Biomatrica Inc Estabilización de trombocitos a temperaturas ambiente
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
JP6564029B2 (ja) 2014-10-14 2019-08-21 ヴァイティー ファーマシューティカルズ，エルエルシー Ｒｏｒ−ガンマのジヒドロピロロピリジン阻害剤
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
CN104860869B (zh) * 2015-04-03 2017-11-03 北京大学 具有mek激酶抑制功能的化合物及其制备方法与应用
HUE050317T2 (hu) 2015-05-20 2020-11-30 Amgen Inc APJ receptor triazol agonistái
DK3331876T3 (da) 2015-08-05 2021-01-11 Vitae Pharmaceuticals Llc Modulators of ror-gamma
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
KR20250047404A (ko) 2015-12-08 2025-04-03 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
WO2018093576A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
SG11201912997TA (en) 2017-06-23 2020-01-30 Cstone Pharmaceuticals Coumarin-like cyclic compound as mek inhibitor and use thereof
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN115650976A (zh) 2017-07-24 2023-01-31 生命医药有限责任公司 RORγ的抑制剂
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
EP3735404B1 (en) 2018-01-02 2023-11-29 Seal Rock Therapeutics, Inc. Ask1 inhibitor compounds and uses thereof
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
US12280055B2 (en) 2021-05-27 2025-04-22 Mirati Therapeutics, Inc. Combination therapies
US20260048075A1 (en) 2022-08-10 2026-02-19 Vib Vzw Inhibition of TCF4/ITF2 in the Treatment of Cancer
WO2026019990A1 (en) 2024-07-18 2026-01-22 Genentech, Inc. Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA920592A (en) 1970-05-28 1973-02-06 Denzel Theodor Amino derivatives of pyrazolo-pyridine carboxylic acids and esters
US3736326A (en) 1971-03-29 1973-05-29 Squibb & Sons Inc Isoxazolopyridine carboxylic acids and esters
US4012373A (en) 1972-09-22 1977-03-15 E. R. Squibb & Sons, Inc. Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones
GB8404586D0 (en) 1984-02-22 1984-03-28 Beecham Group Plc Compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
PL352835A1 (en) 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
JP2002020386A (ja) 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
JP3811775B2 (ja) 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
ES2331246T3 (es) * 2003-07-24 2009-12-28 Warner-Lambert Company Llc Derivados de benzamidazol como inhibidores del mek.
ATE506953T1 (de) 2003-08-07 2011-05-15 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
ATE386715T1 (de) 2003-11-25 2008-03-15 Lilly Co Eli Modulatoren des peroxisomproliferatoraktivierten rezeptors
AU2004299438A1 (en) 2003-12-19 2005-06-30 Biovitrum Ab Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-HT6 receptor-related disorder
JP4805166B2 (ja) 2003-12-22 2011-11-02 バジリア ファルマスーチカ アーゲー アロイルフランおよびアロイルチオフェン
WO2005063296A2 (en) 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
WO2007027855A2 (en) 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
WO2008028141A2 (en) 2006-08-31 2008-03-06 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof

Also Published As

Publication number Publication date
RU2495028C2 (ru) 2013-10-10
WO2010003022A8 (en) 2010-09-30
CA2727252A1 (en) 2010-01-07
ZA201008962B (en) 2012-03-28
KR20110028376A (ko) 2011-03-17
JP2011526924A (ja) 2011-10-20
EP2307364A1 (en) 2011-04-13
MX2010014565A (es) 2011-03-04
EP2307364B1 (en) 2013-06-19
US8492427B2 (en) 2013-07-23
RU2011103434A (ru) 2012-08-10
CL2010001637A1 (es) 2011-07-15
PE20110424A1 (es) 2011-07-22
JP5615274B2 (ja) 2014-10-29
IL209892A0 (en) 2011-02-28
ES2426096T3 (es) 2013-10-21
BRPI0910200A2 (pt) 2015-09-29
US20110124622A1 (en) 2011-05-26
AU2009266953A2 (en) 2011-01-27
CN102137843A (zh) 2011-07-27
WO2010003022A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
EP2307364B1 (en) Isoindolone derivatives as mek kinase inhibitors and methods of use
AU2008343062B2 (en) 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
AU2008343065B2 (en) 5-anilinoimidazopyridines and methods of use
EP2069359B1 (en) Aza-benzothiophenyl compounds and methods of use
AU2008340247B2 (en) Azaindolizines and methods of use
WO2010003025A1 (en) Bicyclic heterocycles as mek kinase inhibitors
AU2014250642A1 (en) Isoindolone derivatives as MEK kinase inhibitors and methods of use
HK1188209B (en) 5-anilinoimidazopyridines and methods of use
HK1147254B (en) 5-anilinoimidazopyridines and methods of use

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 DEC 2010

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted